Key information

🔎 Fund Overview

Repare Therapeutics Inc. is a clinical-stage precision oncology company engaged in developing synthetic lethality (SL) to the discovery and development of novel therapeutics. The Company uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. Using its SNIPRx platform, the Company is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. The Company’s product pipelines include Camonsertib ATR Inhibitor, RP-6306 PKMYT1 Inhibitor and RP-2119 Pol Inhibitor. Its RP-6306 is being developed as a highly potent and selective PKMYT1 inhibitor that preferentially kills tumor cells overexpressing CCNE1.